On September 16, 2021, the Federal Joint Committee (G-BA) has decided that it would not evaluate the proton therapy in a number of indications, including esophageal cancer and inoperable hepatocellular carcinoma (HCC).
Therefore, the method of proton therapy in the abovementioned indications will be removed from Annex II “Methods whose evaluations are paused” of the G-BA Directive “Methods of examination and treatment in hospital settings” and will not be reimbursed. Annex II of the abovementioned Directive includes the methods whose evaluations are paused due to planned ongoing studies with reimbursement provided during this time. The G-BA decision will come into force on the day of the publication in the Federal Gazette.
The full details in German can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.